Pharmacologic proteasome inhibition using Mg132 reduces intestinal inflammation by decreasing intestinal TNFα mRNA in IL10-deficient mice with a CD-like illness (21) and bortezomib, a clinically approved proteasome blocker, attenuates intestinal inflammation in animal models of colitis induced by dextran sulfate (22). Here, TNF is linked to colitis.